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Abstract
With the evolving evidence of the promise of botanicals/biologics for cancer
chemoprevention and treatment, an Indo-U.S. collaborative Workshop focusing
on “Accelerating Botanicals Agent Development Research for Cancer Chemopre-
vention and Treatment” was conducted at the Moffitt Cancer Center, 29–31 May
2012. Funded by the Indo-U.S. Science and Technology Forum, a joint initiative
of Governments of India and the United States of America and the Moffitt Cancer
Center, the overall goals of this workshop were to enhance the knowledge (agents,
molecular targets, biomarkers, approaches, target populations, regulatory stan-
dards, priorities, resources) of a multinational, multidisciplinary team of research-
er’s to systematically accelerate the design, to conduct a successful clinical trials to
evaluate botanicals/biologics for cancer chemoprevention and treatment, and to
achieve efficient translation of these discoveries into the standards for clinical
practice that will ultimately impact cancer morbidity and mortality. Expert panel-
ists were drawn from a diverse group of stakeholders, representing the leadership
from the National Cancer Institute’s Office of Cancer Complementary and Alter-
native Medicine (OCCAM), NCI Experimental Therapeutics (NExT), Food and
Drug Administration, national scientific leadership from India, and a distin-
guished group of population, basic and clinical scientists from the two countries,
including leaders in bioinformatics, social sciences, and biostatisticians. At the
end of the workshop, we established four Indo-U.S. working research collabora-
tive teams focused on identifying and prioritizing agents targeting four cancers
that are of priority to both countries. Presented are some of the key proceedings
and future goals discussed in the proceedings of this workshop.
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Cancer is a leading cause of death worldwide [1] with
deaths projected to continue to rise to over 13.1 million
in 2030. Based on these projections, and in response to
the call for action from the World Health Organization
for a multistakeholder engagement [1], the ultimate goal
of our group is to prioritize and continue to enhance
international collaboration to promote and support the
multidimensional and multisectoral research that is
needed in order to generate or strengthen the evidence-
based cancer prevention and control strategies [2, 3].
Botanicals/biologics have been shown to influence mul-
tiple biochemical and molecular cascades that inhibit
mutagenesis, proliferation, induce apoptosis, and suppress
the formation and growth of human cancers, thus modu-
lating several hallmarks of carcinogenesis. These agents
appear promising in their potential to make a dramatic
impact in cancer prevention and treatment, with a signifi-
cantly superior safety profile than most agents evaluated
to date [4–12]. However, it is clear that although several
botanicals have been characterized and used for hundreds
of years (Traditional Chinese Medicine, Ayurveda, Siddha,
Unani) [3, 13], there have been several challenges and
limitations toward progress in this field. The slow pace of
growth of several of these leads could be attributed to
regulatory protection of classical formulation, lack of
standardization, quality control, mechanism-based studies,
population-based normal range of biomarkers, good labo-
ratory practices, and translational scientists engaged in
conducting well-designed trials. Similarly, in spite of the
national commitment, there are only a few groups in the
United States focused in systematic drug development
using botanicals/biologics. There is, thus, an urgent need
to pool resources and to bring together key stakeholders
to find productive ways to systematically accelerate botan-
icals/biologics drug development for cancer chemopreven-
tion and treatment. Groups working toward similar
objectives could learn from one another’s successes and
failures, furthering progress toward a shared goal
(Extending the Spectrum of Precompetitive Collaboration
in Oncology Research – Workshop Summary Released:
22 July 2010, Institute of Medicine, USA) [2].
Proceedings
The workshop opened with a keynote lecture focused on
“Past Experiences and Lessons Learned from Definitive
Chemoprevention Trials: What Went Wrong? Where Do
We Go From Here? The identification of chemopreven-
tive agents holds tremendous promise in reducing the
burden of cancer. Past trials of preventive agents offer
important lessons that can inform the design and conduct
of future trials. Important lessons learned regarding
agents come from ATBC [4] and CARET [5], which dem-
onstrated the need for more preclinical and early-phase
work before undertaking phase III trials; from BCPT [6]
and STAR [7], which showed that safety can be improved
in iterative generations of agents and trials; from the APC
[8], FAP [9], and aspirin in adenoma prevention trials
[10–12], which highlighted the benefit of preclinical and
Phase II testing, as well as the imperative for broad, sensi-
tive toxicological, and human safety assessments; and
finally the DFMO [10] and Sulindac combination trial,
which demonstrated that synergy between agents can lead
to lower doses, improved efficacy, and fewer or less severe
toxicities. Regarding cohorts, we have learned there are
substantial benefits to employing germline, familial, or
increased-risk cohorts, including, among others, more
power over a shorter time frame. An assessment of end-
points in trials resulting in approval of a preventive agent
reveals that nearly all have been approved on the basis of
intraepithelial neoplasia, particularly in accessible organs.
Lessons gleaned regarding the overall design of clinical
trials underscore the importance of the randomized,
placebo-controlled design and the need for long-term
follow-up and monitoring to meet Food and Drug
Administration requirements and promote acceptance in
the marketplace. Applying these and other lessons to the
design of future chemoprevention trials should facilitate
the translation of novel preventive agents into the clinic
(Table 1).
This session was followed by the current approaches for
screening agents for drug development. Adoption of com-
putational methods to discover new drugs has recently
experienced a true renaissance with several new and excit-
ing techniques being developed and currently employed to
design new drug candidates and to rapidly bring these
agents to the clinic at relatively lower costs. Traditional
approaches to drug discovery have involved target identifi-
cation and validation and lead identification and optimization.
However, in the past decade, several contemporary approaches
and enabling technologies like High-Performance Computing,
Grid Computing, and Cloud Computing have evolved.
Virtual screening and molecular modeling for drug discov-
ery including grid-based docking, quantum mechanics,
molecular mechanics, molecular dynamics, normal-mode
vibration, and mutational analysis were discussed. For
complex diseases like cancer, traditional methods of target-
ing a single protein is found profoundly insufficient laying
the foundation for polypharmacological and combinatorial
analysis harnessing in silico techniques viz. Molecular
Topology, Network Pharmacology, and Combinatorial
Chemistry. A network perspective of complex cancers has
direct implications in the drug discovery process as it
changes the target entity from a single protein to entire
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molecular pathways and/or cellular networks. Examples of
success included the work of the Bioinformatics Group at
the Centre for Development of Advanced Computing
(India) in collaboration with cancer Biomedical Informat-
ics Grid (caBIG®; National Cancer Institute, National
Institute of Health, Rockville, Bethesda, Maryland, USA),
which has developed a grid-enabled web-based automated
pipeline, as well as homology-based prediction of protein
structures, with an emphasis on cancer-related proteins.
Current drug design software also falls short of expecta-
tions even if the structures of drug targets are known [4–6,
13]. Addressing these issues from a physico-chemical
perspective, an approach whereby the development of all
atom energy-based methodologies for whole-genome
analysis (ChemGenome, National Human Genome
Research Institute, National Institutes of Health, Bethesda,
Maryland, www.genome.gov), tertiary structure prediction
of proteins (Bhageerath and Bhageerath-H), and protein/
DNA-targeted lead molecule design (Sanjeevini) was
discussed. These methods can be configured into an
assembly line to deliver hit molecules from genomic
information. The software and a host of other utilities are
freely accessible to the global user community (http://
www.scfbio-iitd.res.in) [14–18]. It was evident that the
availability of contemporary software applications and
infrastructure for collaborative research in both India and
the United States was outstanding and ready for applica-
tion.
This session was followed by presentations of a system-
atic approach using the traditional scientific paradigm to
accelerate agent development using botanicals/biologics
for cancer prevention and treatment in both countries. As
cancers are caused by perturbations of multiple signaling
pathways, the value of promiscuous targeting of botani-
Table 1. Agenda of presentations and presenters at the workshop on botanical/biologics agent development.
Presenter Presentation
Bharat Aggarwal, Ph.D. The Promiscuous Targeting of Multiple Signaling pathways by Botanical and Biologics – Vice or Virtue?
Shrikant Anant, Ph.D. Approaches to development of Novel therapeutic agents based natural dietary compounds for Cancer
Chemoprevention and Treatment
Dr. Kenyon Daniel, Ph.D. Virtual Screening and Molecular Modeling for Drug Discovery
Dr. Gary Deng, MD, Ph.D. Promises and Challenges of Establishing Collaborations with InternationalPartners for Cancer Drug
Development: Our Experience
Dr. Medha Dhurandhar and
Dr. Rajendra Joshi
Combinational analytical approaches for chemopreventive agent development deplying in silico
technologies
Julie Y. Djeu, Ph.D. Icarlin and its derivative, ICT, exert anti-inflammatory, antitumor effects, and modulate myeloid-derived
suppressive cells (MDSCs) functions
Dr. Jinhui Dou, Ph.D. FDA Policy on the US Clinical Trials for Botanical and Biologic Drugs – General versus Specific Guidelines
Shanker Gupta Indo-U.S. Collaborative Research – Opportunities
Dr. Ernest Hawk, M.D., M.P.H. Past Experiences – Lessons Learned (SELECT, CARET, Retinoids vs. Statins, COX-2 inhibitors): What Went
Wrong? Where Do We Go From Here?
Dr. B. Jayaram In Silico Databases as Sources for Chemical structures of Natural Products
Libin Jia, Ph.D. National Commitment to Build Collaborations and Partnerships in Botanical and Biologics for Cancer
Professor Devarajan Karunagaran Strategies to sensitize cancer cells to curcumin-induced apoptosis
Dr. Omer Kucuk, M.D. Botanicals in Prostate cancer Prevention and Treatment
Lalit Kumar, Ph.D. Cancer Chemoprevention and Transdisciplinary Research New Approaches in Cancer Drug Discovery
Dr. Nagi Kumar, Ph.D., R.D., F.A.D.A. Clinical Trials in Prostate and Lung Cancer Chemoprevention
Dr. Mokenge Malafa, M.D. Approach in Developing Botanicals for Pancreatic Cancer
Dr. Cathy Meade, Ph.D. Other Critical Issues in Principles of Research
Jong Park, Ph.D. Preclinical trials for evaluation of safety and effectiveness of botanicals for chemoprevention: The green
tea experience
Sam Petroda International Collaborations in cancer Research and Future Directions
Dr. G. J. Samathanam Currently Funded Projects in the Indian Portfolio of International Collaborations in Cancer Research and
Future Directions
Indian Regulatory Policies that affect Botanical Drug Development
Dr. Fazlul Sarkar, Ph.D. Nutraceutical Research: Bench to Clinic
Dr. Michael Schell, Ph.D. Improved Design of Clinical Trials with Botanicals and Biologics: Statistical Considerations
Professor Maqsood Siddiqi Botanicals for Cancer Treatment and Prevention
Professor Rana P. Singh Multiple Targets of Phytochemicals in Cancer Chemoprevention - Cell Cycle, Apoptosis and Angiogenesis
Anil Srivatsava Model for the future
Dr. Jeffrey D. White, M.D. Currently Funded RO1s, PO1s, R21s, and R03s in Our Portfolio Communication Models-Problems and
Solutions Resources in the United States (Laboratory/Clinical)
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cals/biologics was presented compared with mono-
targeted “smart drugs,” using curcumin as an example of
an agent that targets multiple signaling pathways [19–21].
Additional studies demonstrating a protective role of
curcumin in arsenic-induced lymphocyte DNA damage
with implications as an effective approach to overcome
arsenic toxicity and its consequential adverse health
effects in arsenic-exposed human populations were pre-
sented [22]. Early work on several multitargeting, novel
botanicals such as limonoids from the neem tree
(Azadirachta indica) was reported with research demon-
strating that both azadirachtin and nimbolide significantly
suppressed the viability of HeLa cells in a dose-dependent
manner by inducing cell cycle arrest at G0/G1 phase
accompanied by p53-dependent p21 accumulation and
downregulation of the cell cycle regulatory proteins cyclin
B, cyclin D1, and PCNA [23]. Similarly, nimbolide, a
neem-derived tetranortriterpenoid was shown to concur-
rently abrogate canonical NF-jB and Wnt signaling and
induce intrinsic apoptosis in HepG2 cells [24]. Quercetin
exerts opposing effects on different signaling networks to
inhibit cancer progression, and thus, it is a classic candi-
date for anticancer drug design [25, 26]. Other examples
included 3, 5, 7-trihydroxy-4′-methoxy-8-(3-hydroxy-3-
methylbutyl)-flavone (ICT), a novel derivative of Icariin
(ICA), the major active ingredient of Herba Epimedii.
ICA and, more robustly, ICT directly modulate MDSC
signaling, and therefore altered the phenotype and func-
tion of these cells, both in vitro and in vivo. Icariin medi-
ated the anti-inflammatory functions including
downregulation of TNF-a, PGE2, and nitric oxide and
inhibition of NF-jB p65 activation. Decreased expression
of S100A8/9 observed and inhibition of activation of
STAT3 and AKT may in part be responsible for the
observed results [27].
Presentations that followed focused on elucidating the
molecular mechanism of action of several botanicals/
biologics in preclinical studies and provided examples of
subsequent clinical trial results on human breast, prostate,
colon, and pancreatic cancer patients. The potential
mechanisms of action of lycopene include its antioxidant
and anti-inflammatory, antiproliferative effects as well as
modulation of gene expression through epigenetic effects
[28, 29]. Isoflavones, a potent proteasome inhibitor [30],
produced moderate modulation of steroid hormones and
stabilization or reduction of serum prostate-specific anti-
gen and reduced percentage of cells expressing Ki-67
posttreatment [31, 32] with no toxicity [33]. It was also
observed that genistein downregulates androgen receptor
(AR) expression and produces an increase in FOX01
activity, a pathway that may be more relevant in African
American (AA) men [34]. Significant increase in NF-κB
activity was reported in prostate cancer cells exposed to
chemotherapy and radiation. However, pretreatment with
genistein completely abrogated the chemotherapy and
radiation induced increases in NF-κB. Prostate cancer
patients who received external beam radiation therapy
who received isoflavones demonstrated significant reduc-
tions in radiation-induced toxicity to normal tissue struc-
ture, improvement in the erectile dysfunction, and
urinary continent function [35]. Novel preclinical data on
the combination of isoflavone with conventional thera-
peutics in pancreatic cancer demonstrating safety were
presented [36].
Decursin, a novel coumarin compound, strongly inhib-
its growth and induces death in human prostate carci-
noma DU145, PC-3, and LNCaP cells [37, 38]. Report of
findings revealed that the novel anticancer effects of de-
cursin were mediated via induction of antiangiogenesis,
and cell cycle arrest and apoptosis selectively in human
prostate cancer cells. Preclinical and clinical trial results
on 3, 3′-diindolylmethane (DIM) demonstrated that miR-
34a is typically silenced through methylation in prostate
cancer; however, BR-DIM intervention resulted in the
demethylation of miR-34a promoter, resulting in its re-
expression, which led to the downregulation of AR
expression, one of the target genes of miR-34a [39].
Green tea polyphenols was shown to selectively inhibit
the proteasome activity in intact human prostate cancer
cells and consequently accumulates IkB-a and p27 pro-
teins, leading to growth arrest [40], providing the ratio-
nale for a phase II clinical trial for prostate cancer
prevention [41]. Tocotrienols inhibited NF-κB activity
and the survival of human pancreatic cancer cells in vitro
and in vivo, including observations that the bioactivity of
the four natural tocotrienol compounds (a-, b-, d-, and
c-tocotrienol) was directly related to their ability to sup-
press NF-κB activity in vitro and in vivo. The most bio-
active tocotrienol for pancreatic cancer, d-tocotrienol,
significantly enhanced the efficacy of gemcitabine to inhi-
bit pancreatic cancer growth and survival in vitro and in
vivo and associated with significant suppression of NF-κB
activity and the expression of NF-κB transcriptional
targets [42].
Attempts to understand the cellular origin of cancer
have advanced the theory of cancer stem cells (CSCs).
These rare CSCs have indefinite proliferative potential
and are believed to be responsible for tumor invasiveness
and heterogeneity. Research approaches and rationale
focused on identifying botanicals/biologics for prevention
and therapy that target the stem cells were presented [43].
The CSC hypothesis asserts that malignancies arise in
tissue stem and/or progenitor cells through the dysregula-
tion or acquisition of self-renewal [44]. In a study to
determine whether the dietary polyphenols, curcumin,
and piperine are able to modulate the self-renewal of nor-
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mal and malignant breast stem cells, the effects of these
compounds on mammosphere formation, expression of
the breast stem cell marker aldehyde dehydrogenase
(ALDH), and Wnt signaling were examined. Results dem-
onstrated that curcumin and piperine separately, and in
combination, inhibit breast stem cell self-renewal but do
not cause toxicity to differentiated cells [45]. Stem cell
signaling pathways, self-renewal, epigenetics of stem cell
regulatory elements could be used as efficacy surrogate
biomarkers in clinical trials of both cancer preventive and
treatment compounds [46]. It was evident from these
presentations and discussions that the current and on-
going research in this field was substantial, with a prom-
ise of several novel agents in the pipeline, poised to be
evaluated in phase I–III clinical trials to ultimately reach
the patient’s bedside.
Representatives from the regulatory bodies from India
and United States discussed potential challenges and suc-
cesses for international collaborative research. FDA, USA,
published a draft Guidance for Industry-Botanical Drug
Products (Guidance) in 2000 and finalized the Guidance
in 2004, to illustrate the current thinking on the develop-
ment of botanical drugs. The FDA Policy on the U.S. Clin-
ical Trials for Botanical and Biologic Drugs and the
Investigational New Drug Approval process was presented.
Representatives from the Science and Technology Forum
(India) described that the efforts are ongoing to uplift the
infrastructure development and international harmoniza-
tion of laboratories R&D through GLP, National Accredi-
tation Board of Testing and Calibration of Laboratory,
Metabolic Wards for GCP, Revision of Ethical Guidelines
for Biomedical Research on Human and Animal research
and Clinical Trial Registry (CTRI), and it is mandatory
according to Drugs Controller General India that all the
clinical trials undertaken in India need to be registered
with CTRI. Examples of experience working with regula-
tory agencies and international pharmaceutical companies
in early phase I–II clinical trials using agents’ ranges from
highly defined extract from Maitake mushroom, crude
extract from a single herb Coptis sinensis, and two complex
herbal formulations requiring investigator-initiated IND
approvals from FDA were presented [47, 48]. Building a
team that combines complementary expertise, communi-
cates well, and ensures development of personal relation-
ships was critical for success with international
collaborations. Other critical issues discussed included sta-
tistical considerations, cultural, literacy, economic, and
social considerations when designing clinical trials.
It was reported that approximately $114 million of an
NCI budget of $5 billion directly supports complemen-
tary and alternative medicine (CAM) research, including
research of botanicals and botanical-related products. In
fiscal year (FY) 2010, over 340 of grants funded by NCI
supported CAM research, and about 15% of these sup-
ported botanical or botanical-related research [49]. The
Office of Cancer Complementary and Alternative Medi-
cine (OCCAM) of the NCI is working to build a
research portfolio with areas of special interest that
includes identifying Novel Therapeutics from the Phar-
macopeia of Traditional Medical Systems and provided
examples of a funded trial of Chinese Herbal Medi-
cine PHY906 [50, 51] as a Novel Paradigm for Cancer
Chemotherapy. In India, the primary funding groups
include the Indo-U.S. Science and Technology Forum
with support from Central, State government agencies,
and private foundations.
Future Directions
On the final day of the workshop, four collaborative work-
ing groups focused on initiating collaborative research pro-
jects using the traditional and novel funding mechanisms
in both countries were established. We plan to establish a
joint repository of botanicals/biologics ready for prioritiza-
tion for preclinical and clinical trials, targeting major can-
cers in both countries. Guided by an independent advisory
board of stakeholders from India and the United States, the
group continues to communicate regularly with future
meetings scheduled during national and international sci-
entific conferences. It is clear that both countries have their
strengths and resources, which when combined can actively
facilitate the building of an interdisciplinary community
harnessing system of Information and Communications
Technology toward accelerating botanicals and biologic
drug development on an international scale for cancer pre-
vention and treatment. Of significant importance is also
the impact this approach is likely to have on the economics
of drug discovery. We predict that this collaborative effort
can result in research breakthroughs, which will not only
bring new hope but also create a new class of anticancer
drugs that will help millions of cancer patients and those
at high risk for this disease in both our countries and will
benefit the world population at large.
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